Skip to main content
Evidence Snapshot

Histone deacetylase 5

CHEMBL2563 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2563
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 5 as ChEMBL target CHEMBL2563, mapped to UniProt Q9UQL6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2563
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UQL6
Histone deacetylase 5
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histone deacetylase 5 matters

As of 2026-09-14

Histone deacetylase 5 is reviewed as Histone deacetylase 5 (UniProt Q9UQL6); the current evidence base includes 10 approved drugs, 1017 compounds, and 318 assays, with lead potency reaching pChEMBL 9.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 1017 compounds, and 318 assays for this target. The dominant activity type is IC50. CHEMBL483254 is the current potency anchor at pChEMBL 9.2.

Use CHEMBL483254 as the tractability anchor when discussing potency (pChEMBL 9.2).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 9.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histone deacetylase 5 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UQL6, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1017
Total Compounds
318
Total Assays
10
Approved Drugs
IC50: 1027.0, KI: 95.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL483254
 9.2 Ki Approved
No preferred name
CHEMBL98
 9.0 IC50 Approved
No preferred name
CHEMBL3692689
 8.9 IC50 —
No preferred name
CHEMBL5964075
 8.7 IC50 —
No preferred name
CHEMBL2105763
 8.7 Ki Clinical

Approved Drugs

Structure Compound First Approval
GIVINOSTAT
CHEMBL1213492
 2024
PANOBINOSTAT
CHEMBL483254
 2015
BELINOSTAT
CHEMBL408513
 2014
ROMIDEPSIN
CHEMBL343448
 2009
BENDAMUSTINE
CHEMBL487253
 2008
VORINOSTAT
CHEMBL98
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2563